Approval of omaveloxolone for Friedreich ataxia

Nature Reviews Neurology, Published online: 03 April 2024; doi:10.1038/s41582-024-00957-9The recent approval of omaveloxolone for the treatment of Friedreich ataxia in the USA and Europe represents an important milestone in the field of rare neurological diseases. However, many challenges lie ahead, including the translation of trial results into clinical practice, and the management of patients’ expectations.
Source: Nature Reviews Neurology - Category: Neurology Authors: Source Type: research